Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||INCB054329 + Itacitinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|INCB054329||INCB-054329||BET Inhibitor (Pan) 30||INCB054329 is BET inhibitor, which results in decreased expression of BET protein-regulated genes including MYC, potentially leading to decreased tumor cell proliferation (PMID: 30206163)|
|Itacitinib||INCB039110|INCB-039110|INCB 039110||JAK1 Inhibitor 10||Itacitinib (INCB039110) is a selective inhibitor of Janus kinase 1 (JAK1), which may inhibit cell proliferation (PMID: 25605813, PMID: 32861662).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||INCB054329 + Itacitinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, INCB054329 and Itacitinib (INCB039110) demonstrated synergy in a myeloma cell line in culture, resulting in decreased viability, increased apoptosis, and increased inhibition of STAT3 phosphorylation, and treatment with the combination of INCB054329 and Itacitinib (INCB039110) resulted in increased efficacy in myeloma cell line xenograft models over either agent alone (PMID: 30206163).||30206163|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|